FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/19/2026
Back to search
Official data from USPTO
LIVESPO A FUTURE WITHOUT ANTIBIOTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
04/03/2026
Trademark type
Combined
Nice classes
5
Filing date
11/30/2023
Registration date
05/06/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/06/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
99
Owner location
VN
Examiner
CORWIN, KEVIN SCOTT
Law office
M30
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the stylized wording LIVESPO with the wording LIVE being in grey and SPO being in dark blue. Below this wording appears the smaller stylized wording A FUTURE WITHOUT ANTIBIOTICS in grey. All the aforementioned appears on a white background.
Holders and representatives
Holders
LIVESPO GLOBAL JOINT STOCK COMPANY
Representatives
Christopher Bennett Technology Innovation Law, LLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceuticalspharmaceutical preparations for supportive treatment and prevention of intestinal diseasesincluding dysbiosis in the nature of imbalanced microbiotainflammatory bowel disease (IBD)irritable bowel syndrome (IBS)diarrheaconstipationanorexiaunderweight; Pharmaceuticalspharmaceutical preparations for supportive treatment and prevention of respiratory diseasesrunny nosenasal congestionallergic rhinitiscoughrespiratory infections caused by RSV and influenza virus; Pharmaceuticalspharmaceutical preparations for supportive treatment and prevention of dental diseasesincluding tooth decay and periodontitis; Pharmaceuticalspharmaceutical preparations for supportive treatment and prevention of vaginal disorderssuch as itchingirritationunpleasant odorabnormal dischargediscoloration of vaginal secretions; Pharmaceuticalspharmaceutical preparations for supportive treatment and prevention of skin diseasesincluding mild to moderate acneoily skinatopic dermatitis; Dietetic foods adapted for medical use; Bio-products for medical purposesbiological preparations for the treatment of supportive treatment and prevention of intestinal diseasesincluding dysbiosis in the nature of imbalanced microbiotainflammatory bowel disease (IBD)irritable bowel syndrome (IBS)diarrheaconstipationanorexiaunderweight; Bio-products for medical purposesbiological preparations for the treatment of supportive treatment and prevention of respiratory diseasesrunny nosenasal congestionallergic rhinitiscoughrespiratory infections caused by RSV and influenza virus; Bio-products for medical purposesbiological preparations for the treatment of supportive treatment and prevention of dental diseasesincluding tooth decay and periodontitis; Bio-products for medical purposesbiological preparations for the treatment of supportive treatment and prevention of vaginal disorderssuch as itchingirritationunpleasant odorabnormal dischargediscoloration of vaginal secretions; Bio-products for medical purposesbiological preparations for the treatment of supportive treatment and prevention of skin diseasesincluding mild to moderate acneoily skinatopic dermatitis
Publications
History of USPTO decisions and trademark events.
31 publications found
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
12/02/2025
XXCR
GENERIC MADRID TRANSACTION CREATED
12/01/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
09/12/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
08/27/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
08/27/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/06/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/06/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
05/06/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/18/2025
PUBO
PUBLISHED FOR OPPOSITION
03/18/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/12/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/21/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/21/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/20/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
02/20/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
02/12/2025
GNFR
FINAL REFUSAL E-MAILED
02/12/2025
CNFR
FINAL REFUSAL WRITTEN
02/12/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/23/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/23/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/23/2025
RFNT
REFUSAL PROCESSED BY IB
08/17/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/29/2024
RFRR
REFUSAL PROCESSED BY MPU
07/29/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/29/2024
CNRT
NON-FINAL ACTION WRITTEN
06/28/2024
DOCK
ASSIGNED TO EXAMINER
06/27/2024
MAFR
APPLICATION FILING RECEIPT MAILED
04/05/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/01/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/28/2024
Continuous trademark protection
Get notified about every new filing that threatens LIVESPO A FUTURE WITHOUT ANTIBIOTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.